Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Zhang, Xuefeng; Wang, Jing; Lü, Jing; Li, Rongrong; Zhao, Shuli

doi:10.1186/s12985-018-1026-3

Cited by 3 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibilities for adenoviral vectors usage are endless, several other studies are underway for malaria ( Ewer et al, 2015 ; Hollingdale et al, 2017 ); Ebola ( Matz et al, 2019 ) and Marburg virus ( Dulin et al., 2021 ), Influenza virus ( Kerstetter et al, 2021 ), Dengue virus ( Khanam et al, 2009 ; George and Eo, 2011 ), Chikungunya virus ( Campos et al, 2019 ; Folegatti et al, 2021 ) and Zika virus ( Bullard et al, 2020 ; López-Camacho et al, 2020 ), Hepatitis B virus (HBV) ( Zhang et al, 2018b ; Chinnakannan et al, 2020 ), Hepatitis C virus (HCV) ( Agrawal et al, 2019 ; Hartnell et al, 2020 ), Human Respiratory Syncytial virus (HRSV) ( Gomi et al, 2018 ; Cicconi et al, 2020 ; Williams et al, 2020 ), Nipah virus (NiV) ( van Doremalen et al, 2019 ), Human Papillomavirus (HPV) ( Li et al, 2016 ; Wu et al, 2018 ), Rotavirus ( Xie et al, 2015 ) and many more. Adding to this, veterinary application, against pathogens like Foot-and-mouth disease virus (FMD) ( Diaz-San Segundo et al, 2017 ), Rift Valley fever virus ( Stedman et al, 2019 ), Rabies virus ( Wang et al, 2019b ), Rabbit hemorrhagic disease virus (RHDV) ( Jiang et al, 2018 ), African Swine Fever virus ( Lokhandwala et al, 2017 ), Porcine Reproductive and Respiratory Syndrome virus ( Zhu et al, 2014 ), Feline Immunodeficiency virus ( Gonin et al, 1995 ) and much more.…”

Section: Use Of Adenoviral Vectors As Vaccinesmentioning

confidence: 99%

The use of adenoviral vectors in gene therapy and vaccine approaches

et al. 2022

View full text Add to dashboard Cite

Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field.

show abstract

Section: Use Of Adenoviral Vectors As Vaccinesmentioning

confidence: 99%

The use of adenoviral vectors in gene therapy and vaccine approaches

et al. 2022

View full text Add to dashboard Cite

show abstract

“…So, in the originally published article [1], the “Ad-HBV” appeared throughout the whole paper for 41 times should be replaced by “T101”.…”

Section: Correctionmentioning

confidence: 99%

“…Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China. So, in the originally published article [ 1 ], the “Ad-HBV” appeared throughout the whole paper for 41 times should be replaced by “T101”.…”

Section: Correctionmentioning

confidence: 99%

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Zhang¹,

Wang²,

Lü³

et al. 2018

Virol J

Self Cite

View full text Add to dashboard Cite

“…Efforts to develop novel vaccines include the use of RNA-and viral vector-based approaches. RNA lipid nanoparticle (LNP) formulations and adenovirus (AdV)-based vaccines have performed well in pre-clinical studies [9][10][11]. Recombinant adeno-associated viral vectors (rAAVs) have also been explored for vaccine development.…”

Section: Introductionmentioning

confidence: 99%

AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy

Jacobs,

Dogbey,

Mnyandu

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Hepatitis B virus (HBV) has afflicted humankind for decades and there is still no treatment that can clear the infection. The development of recombinant adeno-associated virus (rAAV)-based gene therapy for HBV infection has become important in recent years and research has made exciting leaps. Initial studies, mainly using mouse models, showed that rAAVs are non-toxic and induce minimal immune responses. However, several later studies demonstrated rAAV toxicity, which is inextricably associated with immunogenicity. This is a major setback for the progression of rAAV-based therapies toward clinical application. Research aimed at understanding the mechanisms behind rAAV immunity and toxicity has contributed significantly to the inception of approaches to overcoming these challenges. The target tissue, the features of the vector, and the vector dose are some of the determinants of AAV toxicity, with the latter being associated with the most severe adverse events. This review discusses our current understanding of rAAV immunogenicity, toxicity, and approaches to overcoming these hurdles. How this information and current knowledge about HBV biology and immunity can be harnessed in the efforts to design safe and effective anti-HBV rAAVs is discussed.

show abstract

Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Cited by 3 publications

References 28 publications

The use of adenoviral vectors in gene therapy and vaccine approaches

The use of adenoviral vectors in gene therapy and vaccine approaches

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy

Contact Info

Product

Resources

About